Raner Gavin, Hu Yirui, Trowbridge Cody, Zhang Li, Logan John, Wu Xianren, Zhang Xiaopeng
Medicine and Surgery, School of Medicine, University of Western Ontario, London, CAN.
Population Health Sciences, Geisinger Commonwealth School of Medicine, Danville, USA.
Cureus. 2024 Feb 13;16(2):e54144. doi: 10.7759/cureus.54144. eCollection 2024 Feb.
The conventional method of heparin and protamine management during cardiopulmonary bypass (CPB) is based on total body weight which fails to account for the heterogeneous response to heparin in each patient. On the other hand, the literature is inconclusive on whether individualized anticoagulation management based on real-time blood heparin concentration improves post-CBP outcomes.
We searched databases of Medline, Excerpta Medica dataBASE (EMBASE), PubMed, Cumulative Index to Nursing and Allied Health Literature (CINHL), and Google Scholar, recruiting randomized controlled trials (RCTs) and prospective studies comparing the outcomes of dosing heparin and/or protamine based on measured heparin concentration versus patient's total body weight for CPB. Random effects meta-analyses and meta-regression were conducted to compare the outcome profiles. Primary endpoints include postoperative blood loss and the correlation with heparin and protamine doses, the reversal protamine and loading heparin dose ratio; secondary endpoints included postoperative platelet counts, antithrombin III, fibrinogen levels, activated prothrombin time (aPTT), incidences of heparin rebound, and re-exploration of chest wound for bleeding.
Twenty-six studies, including 22 RCTs and four prospective cohort studies involving 3,810 patients, were included. Compared to body weight-based dosing, patients of individualized, heparin concentration-based group had significantly lower postoperative blood loss (mean difference (MD)=49.51 mL, 95% confidence interval (CI): 5.33-93.71), lower protamine-to-heparin dosing ratio (MD=-0.20, 95% CI: -0.32 ~ -0.12), and higher early postoperative platelet counts (MD=8.83, 95% CI: 2.07-15.59). The total heparin doses and protamine reversal were identified as predictors of postoperative blood loss by meta-regression.
There was a significant correlation between the doses of heparin and protamine with postoperative blood loss; therefore, précised dosing of both could be critical for reducing bleeding and transfusion requirements. Data from the enrolled studies indicated that compared to conventional weight-based dosing, individualized, blood concentration-based heparin and protamine dosing may have outcome benefits reducing postoperative blood loss. The dosing calculation of heparin based on the assumption of a one-compartment pharmacokinetic/pharmacodynamic (PK/PD) model and linear relationship between the calculated dose and blood heparin concentration may be inaccurate. With the recent advancement of the technologies of machine learning, individualized, precision management of anticoagulation for CPB may be possible in the near future.
体外循环(CPB)期间肝素和鱼精蛋白的传统管理方法基于总体重,这未能考虑到每位患者对肝素的异质性反应。另一方面,关于基于实时血液肝素浓度的个体化抗凝管理是否能改善CPB术后结局,文献尚无定论。
我们检索了医学文献数据库(Medline)、医学文摘数据库(EMBASE)、PubMed、护理学与健康相关文献累积索引(CINHL)以及谷歌学术,纳入比较基于实测肝素浓度与患者总体重进行肝素和/或鱼精蛋白给药用于CPB的随机对照试验(RCT)和前瞻性研究。进行随机效应荟萃分析和荟萃回归以比较结局情况。主要终点包括术后失血量及其与肝素和鱼精蛋白剂量的相关性、鱼精蛋白逆转剂量与肝素负荷剂量之比;次要终点包括术后血小板计数、抗凝血酶III、纤维蛋白原水平、活化部分凝血活酶时间(aPTT)、肝素反跳发生率以及因出血再次开胸探查的情况。
共纳入26项研究,包括22项RCT和4项前瞻性队列研究,涉及3810例患者。与基于体重给药相比,基于肝素浓度的个体化组患者术后失血量显著更低(平均差(MD)=49.51 mL,95%置信区间(CI):5.33 - 93.71),鱼精蛋白与肝素给药比更低(MD = -0.20,95% CI:-0.32 ~ -0.12),术后早期血小板计数更高(MD = 8.83,95% CI:2.07 - 15.59)。通过荟萃回归确定肝素总剂量和鱼精蛋白逆转量为术后失血量的预测因素。
肝素和鱼精蛋白剂量与术后失血量之间存在显著相关性;因此,精确给药对于减少出血和输血需求可能至关重要。纳入研究的数据表明,与传统的基于体重给药相比,基于血液浓度的肝素和鱼精蛋白个体化给药可能在减少术后失血量方面具有结局优势。基于一室药代动力学/药效学(PK/PD)模型假设以及计算剂量与血液肝素浓度之间的线性关系来计算肝素剂量可能不准确。随着机器学习技术的最新进展,在不久的将来,体外循环抗凝的个体化精准管理可能成为现实。